RT Journal Article
SR Electronic
T1 Influence of sex on disease severity in children with COVID-19 and Multisystem Inflammatory Syndrome in Latin America
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.07.21251212
DO 10.1101/2021.02.07.21251212
A1 Brizuela, Martin
A1 Lenzi, Jacopo
A1 Ulloa-Gutiérrez, Rolando
A1 Yassef, Antúnez-Montes Omar
A1 Aida, Jorge Alberto Rios
A1 del Aguila, Olguita
A1 Arteaga-Menchaca, Erick
A1 Campos, Francisco
A1 Uribe, Fadia
A1 Buitrago, Andrea Parra
A1 Londoño, Lina Maria Betancur
A1 Gómez-Vargas, Jessica
A1 Yock-Corrales, Adriana
A1 Buonsenso, Danilo
YR 2021
UL http://medrxiv.org/content/early/2021/02/09/2021.02.07.21251212.abstract
AB Data from adult studies how that COVID-19 is more severe in men than women. However, no data are available for the pediatric population. For this reason, we performed this study aiming to understand if sex influenced disease severity and outcomes in a large cohort of latin-american children with COVID-19 and Multisystem Inflammatory Syndrome (MIS-C). We found that a higher percentage of male children developed MIS-C (8.9% vs 5% in females) and died (1.2% and 0.4% in females), although on multivariate adjusted analyses the only statistically significant difference was found in need of hospitalization, with females less frequently admitted compared with boys (25.6% vs 35.4%). This data are preliminary and need further independent studies to better assess the role of sex.Competing Interest StatementThe authors have declared no competing interest.Funding Statementnothing to declareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the CoviD in south american children study Group core group and approved by the Ethics Committee of the coordinating center and by each participating center (Mexico: COMINVETICA30072020CEI0100120160207; Colombia: PECEIFT06; Peru: No. 42IETSIESSALUD2020; Costa Rica: CECHNN2432020). The study was conducted in accordance with the Declaration of Helsinki and its amendments. No personal or identifiable data were collected during the conduct of this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesavailable upon request to the corresponding author